AGEN - Agenus Inc.
| Previous Close | 3.76 |
| Open | 3.75 |
| Bid | 3.84 x 1800 |
| Ask | 4.00 x 100 |
| Day's Range | 3.63 - 3.81 |
| 52 Week Range | 3.24 - 6.19 |
| Volume | 1,452,254 |
| Avg. Volume | 1,675,634 |
| Market Cap | 387.665M |
| Beta | 2.88 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.23 |
| Earnings Date | Jul 28, 2017 - Jul 31, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 7.00 |
- Zacks•5 days ago
Why Is Agenus (AGEN) Down 17.7% Since its Last Earnings Report?
Agenus (AGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Market Realist•9 days agoIncyte Advances R&D Strategy with Multiple Partnerships
In January 2015, Incyte (INCY) entered an antibody discovery collaboration with Agenus (AGEN), which was later amended in February 2017. As per the amended agreement, the ongoing research programs for the development of checkpoint modulator antibodies targeted at GITR and OX40 have been converted from co-funded ones to being fully funded by Incyte. Additionally, the profit-sharing arrangement for these research programs has been converted into royalty-bearing programs.
- Simply Wall St.•9 days ago
Will Agenus Inc’s (NASDAQ:AGEN) Earnings Grow Over The Next Few Years?
Agenus Inc’s (NASDAQ:AGEN) announced its latest earnings update in December 2017, which indicated company earnings became less negative compared to the previous year’s level as a result of recent tailwindsRead More...
- PR Newswire•10 days ago
Three Agenus Abstracts Accepted for Presentation at the American Association for Cancer Research (AACR) 2018 Annual Meeting
LEXINGTON, Mass. , April 11 , 2018 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, today announced that three ...
- PR Newswire•23 days ago
Agenus to Present at Healthcare Investor Conferences In April
LEXINGTON, Mass., March 29, 2018 /PRNewswire/ -- Agenus Inc. (AGEN), an immune-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, announced today that members of the Company's leadership will present and host one-on-one meetings at two healthcare investment conferences in April. Jennifer Buell, Ph.D., Chief External Affairs and Communications Officer of Agenus, will present on Agenus and AgenTus at the Jefferies IO Cell Therapy Summit on April 3, 2018, at the Boston Harbor Hotel, Boston, Massachusetts. Corporate presentation is at 7:55 a.m. ET.
- Zacks•last month
Agenus (AGEN) Q4 Loss Wider Than Expected, Revenues Miss
Agenus (AGEN) posts wider-than-expected loss and misses on revenue estimate in the fourth quarter of 2017.
- Thomson Reuters StreetEvents•last month
Edited Transcript of AGEN earnings conference call or presentation 15-Mar-18 3:00pm GMT
Q4 2017 Agenus Inc Earnings Call
- Zacks•last month
Agenus (AGEN) Reports Wider than Expected Q4 Loss, Sales Miss
Agenus reports wider than expected loss and misses sales estimates in the fourth quarter of 2017.
- Associated Press•last month
Agenus reports 4Q loss
The Lexington, Massachusetts-based company said it had a loss of 35 cents per share. The biotechnology company posted revenue of $8.4 million in the period. For the year, the company reported that its ...
- PR Newswire•last month
Agenus Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update
LEXINGTON, Mass. , March 15, 2018 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, provided a corporate update ...
- ACCESSWIRE•last month
Agenus Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / March 15, 2018 / Agenus Inc. (NASDAQ: AGEN ) will be discussing their earnings results in their Q4 Earnings Call to be held on March 15, 2018 at 11:00 AM Eastern Time. To listen ...
GuruFocus.com•last monthSteven Cohen Takes Stake in Biotech Company Agenus
Guru expands position in health care space
- PR Newswire•last month
Agenus to Report Fourth Quarter and Full Year 2017 Financial Results on March 15, 2018 and Host Conference Call and Webcast
LEXINGTON, Mass. , March 7, 2018 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, will release its fourth quarter ...
- Simply Wall St.•last month
Has Agenus Inc (NASDAQ:AGEN) Improved Earnings Growth In Recent Times?
For investors with a long-term horizon, assessing earnings trend over time and against industry benchmarks is more valuable than looking at a single earnings announcement in one point in time.Read More...
- Zacks•2 months ago
4 Market-Beating Sector ETFs & Stocks of February
A few sectors have easily survived the market rout and are crushing the broad market this month.
- Motley Fool•2 months ago
Why Agenus Stock Spiked Tuesday
Agenus' steady march higher accelerated yesterday. Here's why.
- Zacks•2 months ago
What's in Store for Agenus (AGEN) This Earnings Season?
Agenus (AGEN) is expected to provide updates on pipeline candidates when it reports Q4 numbers on Mar 8.
- GlobeNewswire•2 months ago
New Research Coverage Highlights Acacia Research, Zebra Technologies, VSE, Spectrum Pharmaceuticals, Agenus, and Williams Companies — Consolidated Revenues, Company Growth, and Expectations for 2018
NEW YORK, Feb. 21, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Acacia ...
- Motley Fool•2 months ago
Is Agenus Inc. a Buy?
This small biotech stock is a high-risk but potentially high-reward proposition.
- PR Newswire•3 months ago
Agenus Announces Combination Clinical Trials of its Anti-CTLA4 (AGEN1884) & Anti-PD1 (AGEN2034)
LEXINGTON, Mass., Jan. 22, 2018 /PRNewswire/ -- Agenus Inc. (AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, today announced the launch of its combination trial with its proprietary anti-CTLA4 (AGEN1884) and anti-PD1 (AGEN2034) antibodies. This Phase 1/2 clinical trial launched in December 2017 and enrollment into the first cohort has been rapidly completed. The optimal combination dose and schedule will be evaluated in an expansion cohort of patients with inoperable cervical cancer who have relapsed after platinum-containing chemotherapy. In addition, we believe both agents are crucial for combinations with our portfolio of proprietary immune oncology therapeutics," said Garo Armen, Ph.D., Chairman and CEO of Agenus.
- PR Newswire•3 months ago
Agenus Inc. Closes $230 Million Royalty Monetization with HealthCare Royalty Partners
LEXINGTON, Mass. , Jan. 22, 2018 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, today announced the closing ...
- InvestorPlace•3 months ago
3 Biotech Stocks Start Healthy in ’18: Will the Rally Last?
In 2018, the biotech industry is expected to witness a continuation of last year’s favorable trends. Noteworthy among them was the approval of Novartis’ (NYSE:NVS) Kymriah, the first cell-based gene therapy known as CAR-T therapy, which is an innovative treatment option for cancer. Spark Therapeutics’s Luxturna, the first gene therapy to treat a rare, inherited form of childhood blindness, was also approved last year.
- Zacks•3 months ago
BlackRock, Pier One Imports, Alkermes, Vertex Pharmaceuticals and Agenus highlighted as Zacks Bull and Bear of the Day
BlackRock, Pier One Imports, Alkermes, Vertex Pharmaceuticals and Agenus highlighted as Zacks Bull and Bear of the Day
- Zacks•3 months ago
3 Biotech Stocks Start Healthy in '18: Will the Rally Last?
We take a look at some biotech stocks that have witnessed an increase in their share price this year so far and look well positioned for the rest of 2018.
- Motley Fool•3 months ago
Will 2018 Be Agenus Inc.'s Best Year Yet?
Is this under-the-radar immuno-oncology stock set to heat up in 2018?
